Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

G(M2) Ganglioside

Known as: G(M2) Ganglioside [Chemical/Ingredient], Ganglioside, Tay-Sachs Disease, GM2, Ganglioside 
A glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in… Expand
National Institutes of Health

Related topics

Related topics

15 relations
Ganglioside GM2 Ab:ACnc:Pt:Ser:Qn:IAIn BloodNCIt Antineoplastic Agent TerminologyProcess of secretion
Expand

Narrower (2)

NGM-1gangliotriaosylceramide 3'-sulfate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2000
Highly Cited
2000
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Immunization with GMK vaccine (G(M2) ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2000
2000
Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody.
A mouse/human chimeric monoclonal antibody (MAb) KM966, specific for the cell-surface tumor antigen ganglioside GM2, was… Expand
Highly Cited
1997
Highly Cited
1997
Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies
Abstract Natural IgM antibodies against the melanoma cell-surface ganglioside GM2, and IgM antibodies induced by vaccination with… Expand
  • figure 1
  • figure 2
1995
1995
Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Gangliosides, such as GM2, GD2, GD3, and 9-O-acetyl GD3, are receiving attention as targets for antibody-based and vaccine-based… Expand
Highly Cited
1994
Highly Cited
1994
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
PURPOSE To perform a double-blind randomized trial with American Joint Commission on Cancer (AJCC) stage III melanoma patients… Expand
Highly Cited
1994
Highly Cited
1994
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Increasing doses of saponin fraction QS-21 were administered as immunological adjuvant in a Phase 1 trial with a constant dose of… Expand
1990
1990
Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
GM2 ganglioside is a common cell surface constituent of human melanoma and other tumors of neuroectodermal origin, and… Expand
Highly Cited
1989
Highly Cited
1989
Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
The ganglioside GM2 is a differentiation antigen expressed on the cell surface of human malignant melanomas and other cancers of… Expand
  • table 1
  • figure I
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1987
Highly Cited
1987
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
GM2, GD2, and GD3 gangliosides are expressed on the surface of human melanoma cells and represent potential targets for… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
1987
Highly Cited
1987
Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers.
This paper reports the presence of GM2 ganglioside containing N-glycolylneuraminic acid (NeuGc) in human colon cancer tissues… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE